Comparison between the effects of σ receptor ligand JO 1784 and neuropeptide Y on immune functions

European Journal of Pharmacology

Volumn 345, Issue 1, 1998, Pages 79-87

  Song, Cai ^a   Leonard, B E ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Receptor ligand; JO 1784; Lymphocyte proliferation; Neuropeptide Y; Neutrophil phagocytosis

Indexed keywords

IGMESINE; NEUROPEPTIDE Y;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DRUG RECEPTOR BINDING; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RAT;

ANIMALS; CINNAMATES; CORTICOSTERONE; CYCLOPROPANES; IMMUNITY, CELLULAR; INDICATORS AND REAGENTS; INJECTIONS, INTRAVENTRICULAR; LYMPHOCYTE ACTIVATION; MALE; MITOGENS; NEUROPEPTIDE Y; NEUTROPHILS; PHAGOCYTOSIS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SIGMA;

EID: 0032510506     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01592-6     Document Type: Article

References (72)

1. Aakerlund L., Gether U., Fuhlendorff J., Schwarts T.W., Thastrup O. Y1 receptor for neuropeptide Y are coupled to mobilization of intracellular calcium and inhibition of adenylate cyclase. FEBS Lett. 260:1990;73-78.
2. Adrian T.E., Allen J.M., Bloom S.R., Ghatei M.A., Rossor M.R., Roberts G.W., Crow T.J., Tatemoto, Polak J.M. Neuropeptide Y distribution in human brain. Nature. 306:1983;584-586.
3. Barg J., Thomas G.E., Bem W.T., Parnes M.D., Ho A.M., Belcheva M.M., McHale R.J., McLachlan J.A., Tolman K.C., Johnson E.F. In vitro and in vivo expression of opioid and sigma receptors in rat C6 glioma and mouse N18TG2 neuroblastoma cell. J. Neurochem. 63:1994;570-574.
4. Bouchard P., Roman F., Junien J.L., Quirion R. Comparative in vivo and in vitro autoradiography of sigma receptors in the mouse brain: Evidence for in vivo interaction with NPY and CGRR-related peptides. Soc. Neurosci. Abstr. 20:1994;747.
5. Bueno L., Gue M., Fabre C., Junien J.L. Involvement of central dopamine and D1 receptors in stress-induced colonic motor alterations in rats. Brain Res. Bull. 29:1992;135-140.
6. 3H (+)-pentazocine binding sites on cells of the immune system J. Neuroimmunol. 35:1991;153-166.
7. Carr D.J.J., Mayo S., Woolley T.W., Decosta B.R. Immunoregulatory properties of (+)-pentazocine and sigma ligands. Immunology. 77:1992;527-531.
8. Conteras, P.C., Conteras, M.L., O'Donohue, T.L., Lair, C.C., 1988. Biochemical and behavioural effects of sigma and PCP ligands. In: Sigma and Ligands. A.R. Liss, New York, pp. 240-243.
9. Dumont Y., Martel J.C., Fournier A., St-Pierreand S., Quirion R. Neuropeptide Y and neuropeptide Y receptor subtypes in brain and peripheral tissues. Prog. Neurobiol. 38:1992;125-167.
10. Dureus P., Louis D., Grant A.V., Bilfinger T.V., Stefano G.B. Neuropeptide Y inhibits human and invertebrate immunocyte chemotaxis, chemokinesis and spontaneous activation. Cell. Mol. Neurobiol. 13:1993;541-546.
11. Earley B., Burke M., Leonard B.E., Gouret C.J., Junien J.L. Evidence for an anti-amnesic effect of JO 1784 in the rat: A potent and selective ligand for the sigma receptor. Brain Res. 546:1991;282-286.
12. Felten, S.Y., Felten, D.L., Bellinger D.L., Olschowka, A., 1992. Noradrenergic and peptidergic innervation of lymphoid organs. In: Blalock, J.E. (Ed.), Chemical Immunology: Neuroimmunoendocrinology. Karger, Basel, p. 25.
13. Friedman E.M., Irwin M.R., Nonogaki K. Neuropeptide Y inhibits in vivo specific antibody production in rats. Brain Behav. Immun. 3:1995;182-189.
14. Garza H.H., Mayne S., Bowen W.D., DeCosta B.R., Carr D.J.J. Characterization of a (+)-azidophenazocine-sensitive sigma receptor on splenic lymphocytes. J. Immunol. 151:1993;4672-4680.
15. Glick D., von Redlich D., Levine S. Fluorimetric determination of corticosterone and cortisol in 0.02-0.05 ml of plasma or submilligram samples of adrenal tissue. Endocrinology. 74:1964;653-655.
16. 3H ] dopamine release from rat striatal slices by sigma receptor ligands J. Pharmacol. Exp. Ther. 271:1994;212-218.
17. Goto T., Herbermann R.B., Maluish A., Strong D.M. Cyclic AMP as a mediator of prostaglandin E2-induced suppression of human natural killer activity. J. Immunol. 130:1983;1350-1355.
18. Gue M., Yoneda M., Monnikes H., Junien J.L., Tache Y. Central neuropeptide Y and the sigma ligand, JO 1784, reverse corticotropin-releasing factor-induced inhibition of gastric acid secretion in rats. Br. J. Pharmacol. 107:1992;642-647.
19. Gudelsky G.A., Nash J.F. Neuroendocrinological and neurochemical effects of sigma ligands. Neuropharmacology. 31:1992;157-162.
20. Hafstrom I., Ringertz B., Lundeberg T. The effect of endothelin, neuropeptide Y, calcitonin gen-related peptide and substance P on neutrophil functions. Acta Physiol. Scand. 148:1993;341-346.
21. Heilig M., Wahlestedt C., Widerlov E. Neuropeptide Y (NPY)-induced suppression of activity in the rat: Evidence for NPY receptor heterogeneity and for interaction with α-adrenoceptors. Eur. J. Pharmacol. 157:1988;205-213.
22. Heilig M., Vecsei L., Wahlestedt C., Alling C., Widerlov E. Effects of centrally administered neuropeptide Y (NPY) and NPY 13-36 on the brain monoaminergic systems of the rat. J. Neural Transm. 79:1990;193-208.
23. Hosker H.S.R.C., Kelly C., Corris P.A. Assessment of phagocytic function using chemiluminescence. Blood Rev. 3:1989;88-93.
24. Irwin M., Brown M., Patterson T., Hauger R., Mascovich A., Grand I. Neuropeptide Y and natural killer cell activity: Findings in depression and Alzheimer caregiver stress. FASEB J. 5:1991;3100-3107.
25. Irwin M., Hauger R., Brown M. Central corticotropin-releasing hormone activates the sympathetic nervous system and reduces immune function: Increased responsivity of the aged rat. Endocrinology. 131:1992;1047-1053.
26. Junien J.L., Gue M., Bueno L. Neuropeptide Y and sigma ligand (JO 1784) act through a Gi protein to block the psychological stress and corticotropin-releasing factor-induced colonic motor activity in rats. Neuropharmacology. 30:1991;1119-1124.
27. Karbon E.W., Abreu M.E., Erickson R.H., Kaiser C., Natalie K.L. Jr., Clissold D.B., Borosky S., Bailey M. NPC 16377, a potent and selective sigma-ligand. I. Receptor binding, neurochemical and neuroendocrine profile. J. Pharmacol. Exp. Ther. 265:1993;866-875.
28. Lesage A.S., de Loore K.L., Peeters L., Leysen J.E. Neuroprotective sigma ligands interfere with the glutamate-activated NOS pathway in hippocampal cell culture. Synapse. 20:1995;156-164.
29. Lockhar B.P., Soulard P., Benicourt C., Privat A., Junien J.L. Distinct neuroprotective profiles for sigma ligands against NMDA and hypoxia-mediated neurotoxicity in neuronal culture toxicity studies. Brain Res. 675:1995;110-120.
30. 2+ increase in vascular smooth cells. FEBS Lett. 259:1989;79-82.
31. Monnet F.P., Debonnel G., de Montigny C. Neuropeptide Y selectively potentiates N-methyl-D-aspartate-induced neuronal activation. Eur. J. Pharmacol. 192:1990;207-208.
32. Monnet F., Debonnel G., de Montigny C. In vivo electrophysiological evidence for a selective modulation of N-methyl-D-aspartate-induced neuronal activation in rat CA3 dorsal hippocampus by sigma ligands. J. Pharmacol. Exp. Ther. 261:1991;123-130.
33. 3H ]-noradrenaline release in the rat hippocampus: G-protein dependency Arch. Pharmacol. 346:1992;32-39.
34. Monnet F.P., Debonnel G., Fournier A., de Montigny C. Neuropeptide Y potentiates the N-methyl-D-aspartate response in the CA3 dorsal hippocampus. II. Involvement of subtype of sigma receptor. J. Pharmacol. Exp. Ther. 263:1992;1219-1225.
35. 2+ and inhibits adenylate cyclase in human erythroleukemia cells. Am. J. Physiol. 255:1988;E880-885.
36. Nagain C., Chariot J., Roze C. Differential effects of peptide YY, neuropeptide Y, and sigma ligands on neutrally stimulated external pancreatic secretion in the rat. Pancreas. 10:1995;123-130.
37. Nair M.P.N., Schwartz S.A., Wu K., Kronfol Z. Effect of Neuropeptide Y on natural killer activity of normal human lymphocytes. Brain Behav. Immun. 7:1993;70-78.
38. O'Neill B., Leonard B.E. Abnormal zymosan-induced neutrophil chemiluminescence as a marker of depression. J. Affect. Disord. 19:1990;265-272.
39. Quirion, R., Mount, H., Chaudieu, I., Dumont, Y., Boksa, P., 1991. Neuropeptide Y, polypeptide YY, phencyclidine and sigma related agents. Any relationships? In: NMDA and Related Agents: Biochemistry, Pharmacology and Behaviour. NPP Press, Ann Arbour Michigan, pp. 203-210.
40. Quirion R., Bowen W.D., Itzhak Y., Junien J.L., Musacchio J.M., Rothman R.B., Su T.P., Tam S.W., Taylor D. A proposal for the classification of sigma binding sites. Trends Pharmacol. Sci. 13:1992;85-86.
41. Riviere P.J.M., Pascaud X., Junien J.L., Porreca F. Neuropeptide Y and JO1784, a selective σ ligand, alter intestinal ion transport through a common haliperidol-sensitive site. Eur. J. Pharmacol. 187:1990;557-559.
42. Roman F.J., Pascaud X., Duffy O., Vauche D., Martin B., Junien J.L. Neuropeptide Y and peptide YY interact with rat brain σ and PCP binding sites. Eur. J. Pharmacol. 174:1989;301-302.
43. Roman F., Pascaud X., Martin M., Vauche D., Junnien J.L. JO 1784: A potent and selective ligand for rat and mouse brain sigma sites. J. Pharm. Pharmacol. 42:1990;439-440.
44. Roman F., Martin B., Junnien J.L. In vivo interaction of neuropeptide Y and peptide YY and sigma receptor sites in mouse brain. Eur. J. Pharmacol. 242:1993;305-307.
45. Romano T.A., Felten S.Y., Felten D.L., Olschowka J.A. Neuropeptide Y innervation of the rat spleen: Another potential immunomodulatory neuropeptide. Brain Behav. Immun. 5:1991;116-131.
46. Sagratella S., de Carolis S.A., Popoli P. Behavioural and electoencephalographic interactions between haloperidol and PCC/sigma ligands in the rat. Psychopharmacology. 105:1991;485-491.
47. Schalling M., Franco-Cereceda A., Hemsen A., Dagerlind A., Seroogy K., Persson H., Hokfel T., Lundberg J.M. Neuropeptide Y and catecholamine synthesizing enzymes and their mRNA in rat sympathetic neurons and adrenal glands: Studies on expression, synthesis and axonal transport after pharmacological and experimental manipulations using hybridization techniques and radioimmunoassay. Neuroscience. 41:1991;735-766.
48. Smialowska M., Legutko B. Haloperidol-induced increase in neuropeptide Y immunoreactivity in the locus coeruleus of the rat brain. Neuroscience. 47:1992;351-355.
49. Soder O., Hellstrom P.M. Neuropeptide regulation of human thymocyte, guinea pig T-lymphocyte and rat B-lymphocyte mitogenesis. Int. Arch. Allergy Appl. Immunol. 84:1987;205-211.
50. Sonders M.S., Keana J.F.W., Weber E. Phencyclidine and psychotomimetic sigma opiates: Recent insights into their biochemical and physiological sites of action. Trends. Neurol. Sci. 11:1988;37-40.
51. Song C., Leonard B.E. The effects of chronic lithium chloride administration on some behaviour and immune functions in olfactory bulbectomized rats. J. Psychopharmacol. 8:1994;40-47.
52. Song C., Leonard B.E. Serotonin reuptake inhibitors reverse the impairments in behaviour, neurotransmitter and immune functions in the olfactory bulbectomized rat. Hum. Psychopharmacol. 9:1994;135-146.
53. Song C., Leonard B.E. Interleukin-2 induced changes in behaviour, neurotransmitter and immune functions in the olfactory bulbectomized rat: IL-2 may be a modulator of depression in the central nervous system. Neuroimmunomodulation. 2:1995;263-273.
54. Song C., Leonard B.E. The effects of pretreatment of sigma ligand JO1784 on CRF-induced changes in behavioural, neurochemical and immune aspects. Neuropsychobiology. 35:1997;200-204.
55. Song C., Kelly J.P., Leonard B.E. The effect of stressful behavioural exposure on endocrine and immune parameters in the rat. Stress Med. 10:1994;239-245.
56. Song C., Earley B., Leonard B.E. Behavioural, neurochemical, and immunological responses to CRF administration: Is CRF a mediator of stress? Ann. N. Y. Acad. Sci. 771:1995;55-72.
57. Song C., Earley B., Leonard B.E. The effects of central administration of neuropeptide Y on behaviour, neurotransmitter, and immune functions in the olfactory bulbectomized rat model of depression. Brain Behav. Immun. 10:1996;1-16.
58. Su T.P. Pharmacologic characterization of sigma receptors. NIDA Res. Monogr. 133:1993;41-53.
59. Su, T.P., Shuklat, K., Gund, T., 1990. Steroid binding at σ receptors: CNS and immunological implications. In: Wiley, C. (Ed.), Ciba Foundation Symposium, vol. 153. pp. 107-113.
60. 3H SKF 10047 and 3H haloperidol binding in guinea pig brain membranes Proc. Natl. Acad. Sci. USA. 81:1984;5618-5621.
61. Tam S.W., Mitchell K.N. Neuropeptide Y and peptide YY do not bind to brain σ and PCP binding sites. Eur. J. Pharmacol. 193:1991;121-122.
62. Unden A., Bartfai T. Regulation of neuropeptide Y binding by guanine nucleotide in the rat cerebral cortex. FEBS Lett. 177:1984;125-128.
63. van Riezen H., Leonard B.E. Effects of psychotropic drugs on the behaviour and neurochemistry of olfactory bulbectomized rats. Pharmacol. Ther. 47:1990;21-34.
64. Wahlestedt C., Ekman R., Widerlov E. Neuropeptide Y and the central nervous system distribution effects and possible relationships to neurological and psychiatric disorders. Prog. Neuro-Psychopharmacol. 13:1989;31-54.
65. Wahlestedt C., Reis D.J. Neuropeptide Y-related peptides and their receptors-are the receptors potential therapeutic drug targets? Annu. Rev. Pharmacol. Toxicol. 32:1993;309-352.
66. Wahlestedt C., Grundemar L., Håkanson R., Heilig H., Shen G. Neuropeptide Y receptor subtypes. Y1 and Y2. Ann. N. Y. Acad. Sci. 611:1990;7-26.
67. Walker J.M., Bowen W.D., Walker F.O., Matsumoto R.R., de Costa B., Rice K.C. Sigma receptors: Biology and function. Pharmacol. Rev. 42:1990;355-402.
68. Winer, B.J., 1971. Statistical Principles in Experimental Design, 2nd ed. McGraw-Hill, New York.
69. Wolfe Jr., S.A., De Souza E.B. Sigma and phencyclidine receptors in the brain-endocrine-immune axis. NIDA Res. Monogr. 133:1993;95-123.
70. Wolfe, Jr., S.A., De Souza, E.B., 1994. Role of sigma binding sites in the modulation of endocrine and immune functions. In: Itzhak, Y. (Ed.), Sigma Receptors. Academic Press, New York, pp. 288-309.
71. Wolfe Jr., S.A., Culp S.G., De Souza E.B. σ-Receptors in endocrine organs: Identification, characterization, and autoradiographic localization in rat pituitary, adrenal testis, and ovary. Endocrinology. 124:1989;1160-1172.
72. Zhang J., Chiodo L.A., Wettstein J.G., Junien J.L., Freeman A.S. Repeated administration of sigma ligands alters the population activity of rat midbrain dopaminergic neurons. Synapse. 13:1993;223-230.